Identification of Z-Tyr-Ala-CHN

SARS-CoV-2 cathepsin L inhibitor coronavirus in vitro phenotypic screening

Journal

Microorganisms
ISSN: 2076-2607
Titre abrégé: Microorganisms
Pays: Switzerland
ID NLM: 101625893

Informations de publication

Date de publication:
10 Mar 2023
Historique:
received: 13 01 2023
revised: 17 02 2023
accepted: 07 03 2023
medline: 30 3 2023
entrez: 29 3 2023
pubmed: 30 3 2023
Statut: epublish

Résumé

The ongoing COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is partly under control by vaccination. However, highly potent and safe antiviral drugs for SARS-CoV-2 are still needed to avoid development of severe COVID-19. We report the discovery of a small molecule, Z-Tyr-Ala-CHN

Identifiants

pubmed: 36985290
pii: microorganisms11030717
doi: 10.3390/microorganisms11030717
pmc: PMC10055926
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : ASPR HHS
ID : HHSO100201700018C
Pays : United States
Organisme : Advanced Research and Development Authority (BARDA)
ID : HHSO100201800012C
Organisme : Janssen Research & Development
ID : N/A
Organisme : Corona Accelerated R&D in Europe (CARE) project with the Innovative Medicines Initiative 2 Joint Undertaking (JU). The JU receives support from the European Union's Horizon 2020 research and innovation program, EFPIA, Bill & Melinda Gates Foundation, Glob
ID : 101005077
Organisme : Hercules Foundation (Research Foundation Flanders)
ID : NA
Organisme : Rega Foundation, KU Leuven
ID : NA

Références

Lancet Infect Dis. 2022 Jul;22(7):1002-1010
pubmed: 35405090
Int J Biol Sci. 2020 Mar 15;16(10):1724-1731
pubmed: 32226290
N Engl J Med. 2022 Feb 10;386(6):509-520
pubmed: 34914868
Lancet. 2022 Jan 15;399(10321):234-236
pubmed: 34942101
Nat Med. 2021 Nov;27(11):2025-2031
pubmed: 34526698
J Med Virol. 2022 Jul;94(7):3101-3111
pubmed: 35229317
PLoS Comput Biol. 2020 Dec 8;16(12):e1008461
pubmed: 33290397
EBioMedicine. 2021 Mar;65:103255
pubmed: 33676899
Pharmacol Res Perspect. 2022 Feb;10(1):e00909
pubmed: 34968008
J Virol. 2010 Apr;84(7):3210-9
pubmed: 20071581
N Engl J Med. 2021 Jan 7;384(1):20-30
pubmed: 33332779
Traffic. 2009 Jul;10(7):883-93
pubmed: 19582903
J Virol. 2021 Feb 23;95(7):
pubmed: 33622961
J Virol. 2006 Apr;80(7):3180-8
pubmed: 16537586
Biochem J. 1989 Nov 1;263(3):945-9
pubmed: 2597135
Elife. 2021 Jan 04;10:
pubmed: 33393462
J Biomol Screen. 2012 Apr;17(4):496-506
pubmed: 22233649
EBioMedicine. 2021 Dec;74:103663
pubmed: 34768087
Science. 2021 Jul 30;373(6554):541-547
pubmed: 34326236
Sci Immunol. 2022 Jul 29;7(73):eabp9312
pubmed: 35471062
Biochem J. 1988 Aug 1;253(3):751-8
pubmed: 2845932
Pharmacol Rep. 2022 Dec;74(6):1166-1181
pubmed: 36401119
Nat Commun. 2020 May 4;11(1):2251
pubmed: 32366817
Viruses. 2022 Sep 22;14(10):
pubmed: 36298659
J Virol Methods. 2005 Oct;129(1):56-63
pubmed: 15961169
Lancet Infect Dis. 2022 Feb;22(2):183-195
pubmed: 34756186
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Cell. 2021 Feb 4;184(3):775-791.e14
pubmed: 33503446
Mol Ther Nucleic Acids. 2021 Dec 3;26:1107-1114
pubmed: 34692233
Front Public Health. 2021 Aug 06;9:709127
pubmed: 34422750
EBioMedicine. 2021 Oct;72:103595
pubmed: 34571361
J Virol. 2012 Jun;86(12):6537-45
pubmed: 22496216
J Cell Sci. 2006 Oct 1;119(Pt 19):3944-57
pubmed: 16954148
Mil Med Res. 2021 Aug 31;8(1):47
pubmed: 34465396
Mol Pharmacol. 2010 Aug;78(2):319-24
pubmed: 20466822
Proc Natl Acad Sci U S A. 2020 Oct 6;117(40):24620-24626
pubmed: 32883878
Nat Rev Drug Discov. 2022 Dec;21(12):881-898
pubmed: 36008483
PLoS Pathog. 2014 Nov 06;10(11):e1004502
pubmed: 25375324
Trends Parasitol. 2019 Jul;35(7):559-570
pubmed: 31176583
J Virol. 2013 Jun;87(11):6150-60
pubmed: 23536651
Emerg Top Life Sci. 2020 Dec 11;4(4):371-378
pubmed: 33269805
J Phys Chem Lett. 2021 Dec 16;12(49):11850-11857
pubmed: 34873910
J Med Chem. 2020 Nov 12;63(21):12256-12274
pubmed: 32539378
EMBO J. 2021 Aug 16;40(16):e107821
pubmed: 34159616
BMC Biol. 2021 Aug 2;19(1):156
pubmed: 34334126
Chem Sci. 2021 Jul 19;12(32):10825-10835
pubmed: 35355937
Nat Microbiol. 2022 Aug;7(8):1161-1179
pubmed: 35798890
J Gen Virol. 2020 Sep;101(9):925-940
pubmed: 32568027
J Virol. 2016 Dec 16;91(1):
pubmed: 27733646
Viruses. 2021 Apr 28;13(5):
pubmed: 33925255
Nat Commun. 2021 Jan 12;12(1):279
pubmed: 33436624
Antiviral Res. 2015 Apr;116:76-84
pubmed: 25666761
Lancet Respir Med. 2021 May;9(5):522-532
pubmed: 33676590
Signal Transduct Target Ther. 2021 Mar 27;6(1):134
pubmed: 33774649
Sci Rep. 2022 Apr 6;12(1):5825
pubmed: 35388095
J Theor Biol. 2023 Sep 7;572:111568
pubmed: 37393986
J Virol. 2021 Oct 13;95(21):e0097521
pubmed: 34406858
J Virol Methods. 2010 Nov;169(2):365-74
pubmed: 20709108
J Virol. 2018 Jan 30;92(4):
pubmed: 29167338
BMC Pharmacol Toxicol. 2022 Dec 2;23(1):91
pubmed: 36461109
ACS Chem Biol. 2021 Apr 16;16(4):642-650
pubmed: 33787221
ChemMedChem. 2022 Jan 5;17(1):e202100456
pubmed: 34242492
Int J Mol Sci. 2020 May 17;21(10):
pubmed: 32429572
Cell Mol Life Sci. 2021 Apr;78(7):3565-3576
pubmed: 33449149
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Antimicrob Agents Chemother. 2020 May 21;64(6):
pubmed: 32312781
Cell Rep Med. 2021 Oct 19;2(10):100421
pubmed: 34604819
ACS Infect Dis. 2021 Jun 11;7(6):1457-1468
pubmed: 33570381
Thorax. 2022 Feb;77(2):203-209
pubmed: 34404754
Science. 2021 Sep 17;373(6561):1372-1377
pubmed: 34385356
Int J Mol Sci. 2022 May 04;23(9):
pubmed: 35563514
Nat Rev Drug Discov. 2019 Dec;18(12):923-948
pubmed: 31477883
Cell Res. 2022 Mar;32(3):319-321
pubmed: 35064226

Auteurs

Jordi Doijen (J)

Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium.

Koen Temmerman (K)

Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium.

Christel Van den Eynde (C)

Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium.

Annick Diels (A)

Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium.

Nick Van den Broeck (N)

Charles River Laboratories, Turnhoutseweg 30, 2340 Beerse, Belgium.

Michiel Van Gool (M)

Janssen Cilag S.A., C/Jarama 75A, 45007 Toledo, Spain.

Inha Heo (I)

Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium.

Steffen Jaensch (S)

Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium.

Marleen Zwaagstra (M)

Faculty of Veterinary Medicine, Yalelaan 1, Virology Division, Department of Biomolecular Health Sciences, Infectious Diseases and Immunology, Utrecht University, 3584 Utrecht, The Netherlands.

Mayra Diosa Toro (M)

Faculty of Veterinary Medicine, Yalelaan 1, Virology Division, Department of Biomolecular Health Sciences, Infectious Diseases and Immunology, Utrecht University, 3584 Utrecht, The Netherlands.

Winston Chiu (W)

Laboratory of Virology and Chemotherapy, Herestraat 49, Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium.

Steven De Jonghe (S)

Laboratory of Virology and Chemotherapy, Herestraat 49, Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium.

Pieter Leyssen (P)

Laboratory of Virology and Chemotherapy, Herestraat 49, Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium.

Denisa Bojkova (D)

Institute for Medical Virology, University Hospital, Paul-Ehrlich-Str. 40, Frankfurt University, 60596 Frankfurt am Main, Germany.

Sandra Ciesek (S)

Institute for Medical Virology, University Hospital, Paul-Ehrlich-Str. 40, Frankfurt University, 60596 Frankfurt am Main, Germany.

Jindrich Cinatl (J)

Institute for Medical Virology, University Hospital, Paul-Ehrlich-Str. 40, Frankfurt University, 60596 Frankfurt am Main, Germany.

Lore Verschueren (L)

Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium.

Christophe Buyck (C)

Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium.

Frank Van Kuppeveld (F)

Faculty of Veterinary Medicine, Yalelaan 1, Virology Division, Department of Biomolecular Health Sciences, Infectious Diseases and Immunology, Utrecht University, 3584 Utrecht, The Netherlands.

Johan Neyts (J)

Laboratory of Virology and Chemotherapy, Herestraat 49, Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium.

Marnix Van Loock (M)

Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium.

Ellen Van Damme (E)

Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium.

Classifications MeSH